investigating effects of a novel nutraceutical on hypercholesterolaemia in australian adults

Conditions: Hypercholesterolemia

Summary: to evaluate the effects of daily consumption of 3 capsules of swisse nutra+ cholesterol balance on serum ldl-cholesterol in adults with hypercholesterolaemia compared to placebo over four months. this is a single-centre, randomised, double-blind, placebo controlled, parallel study. applicants will be eligible to participate if they have hypercholesterolemia, defined by fasting ldl-cholesterol 2.5mmol/l and ≤5 mmol/l confirmed at screening visit. participants who are otherwise healthy will be included in the study; individuals with a history of cardiovascular disease are excluded from this trial. following pre-screening telephone assessment, applicants will attend an in-clinic screening visit and following informed consent, their general health and eligibility for inclusion into the study will be assessed. on day 1 eligible participants will be randomly allocated to receive one of two study treatments (intervention or placebo). participants will consume the assigned treatment daily for four months. participants will return to the clinic at months 2 and 4 for assessment of primary and secondary outcomes. compliance, adverse events and concomitant medication use will be assessed at these visits. in addition, participants will complete an online survey at months 1 and 3 to assess protocol compliance, adverse events and use of concomitant medications. any queries that arise from the survey will be followed up by phone call. dietary intakes will be assessed at the baseline and four-month visits. a final participant online survey and phone call (if needed) will be conducted one month after the 4-month visit for a final safety assessment.


Eligibility criteria:
inclusion criteria: 1. male or female aged 18-65 inclusive 2. fasting ldl-cholesterol ≥2.5mmol/l and ≤5mmol/l\* confirmed at screening visit 3. low cardiovascular disease (cvd) risk score (for individuals aged 45-65 years, inclusive) determined using framingham risk equation \<10% absolute risk of cvd events over 5 years# as determined using a risk calculator (1) or in the event that this is not available using australian cardiovascular risk charts (2) 4. body mass index (bmi) \>18.5 kg/m2 and \<35 kg/m2 confirmed during screening period and day 1 5. willing to provide written informed consent exclusion criteria: 1. serum ldl-cholesterol \>5 mmol/l\* at screening 2. use of omega-3 supplements at high dose (\>900 mg/day of docosahexaenoic acid (dha) / eicosapentaenoic acid (epa)) 3. use of and not prepared to abstain from lipid lowering medications, supplements or fortified foods containing substances that may, in the opinion of the medical investigator, affect lipid concentrations (e.g. statins, metformin, fibrates, cholesterol absorption inhibitors, nicotinic acid, or omega-3 supplements \<900 mg/day dha/epa) , soluble fibre, e.g. β-glucan/psyllium, plant sterols, curcumin/turmeric) within past 28 days of day 1 4. previous diagnosis of chronic disease such as cvd, diabetes, cancer, familial hypercholesterolaemia, kidney disease 5. smoking (i.e. history of smoking within the last six months) 6. serum triglycerides \>4.5mmol/l (ldl-cholesterol concentrations are unreliable in the presence of high triglyceride levels) 7. women of childbearing potential (wocbp) who: 1. are not currently using effective methods of contraception and 2. have not been using effective methods of contraception for 14 days prior to day 1 and 3. are not willing to use effective methods of contraception throughout the study 8. wocbp who have a positive urine dipstick pregnancy test at screening or day 1, or currently pregnant or lactating 9. untreated hypertension (blood pressure ≥140/90mmhg) 10. aversion and/or intolerance/allergy to the study intervention products \^ 11. unwilling or unable to maintain usual levels of physical activity for the duration of the study 12. history of or known presence of alcohol abuse or illicit drug use, any surgical history, clinically significant conditions (i.e. renal, or urological disease, liver disease gastrointestinal disease or any other significant disease) or organ dysfunction that in the opinion of the investigator may affect the participant's ability to participate in the study or the study results 13. currently hospitalised or any planned hospitalisations during the study or up to one month following the last dose of the study product that may affect the participant's ability to comply with the study in the opinion of the medical investigator 14. received an investigational drug within 3 months prior to day 1 that in the opinion of the investigator may affect the applicant's ability to participate in the study or the study results

Keywords: hypercholesterolemia low-density lipoprotein nutraceutical bergamot artichoke phytosterols hydroxytyrosol